Purpose of Review

Thrombocytosis is common to all myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis. Despite the traditionally held belief amongst many clinicians that thrombocytosis correlates with thrombosis risk, there is little evidence in the literature to support that claim. Herein we critically analyze the literature to better understand the relationship between thrombocytosis and risk of thrombosis in MPN.

Recent Findings

Both retrospective and prospective studies argue against associations between thrombocytosis and risk of thrombosis in patients with ET and PV. Rather, most studies suggest that the presence of extreme thrombocytosis is instead associated with an increased risk of hemorrhagic events, a paradoxical phenomenon with important clinical implications.

Summary

Thrombosis risk has a multifactorial set of etiologies in MPNs. While qualitative abnormalities of the platelets may contribute, associations between platelet quantity and thrombosis risk are weak in MPN patients.

中文翻译：

---

血小板增多和血栓形成：确实存在相关性吗？

审查目的

血小板增多症是所有骨髓增生性肿瘤（MPN）所共有的，包括原发性血小板增多症（ET），真性红细胞增多症（PV）和骨髓纤维化。尽管许多临床医生一直认为血栓形成与血栓形成风险相关，但文献中很少有证据支持这种说法。在这里，我们批判性地分析文献，以更好地理解MPN中血小板增多与血栓形成风险之间的关系。

最近的发现

回顾性和前瞻性研究均反对ET和PV患者的血小板增多与血栓形成风险之间的关联。相反，大多数研究表明，极端血小板增多症与出血性事件风险增加有关，而出血性事件是一种具有重要临床意义的自相矛盾现象。

概要

在MPN中，血栓形成风险具有多种病因。尽管血小板的质性异常可能会导致，但MPN患者的血小板数量与血栓形成风险之间的关联较弱。